NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline. SO WHAT: If you purchased Sage securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...

NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"), of the important October 28, 2024 lead plaintiff deadline. SO WHAT: If you purchased Sage securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sage Therapeutics investors who were adversely affected by alleged securities fraud between April 12, 2021 and July 23, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sag ...

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sage-therapeutics-loss-submission-form/?id=107861&from=4 CLASS PERIOD: April 1 ...

Shares of Sage Therapeutics, Inc. (SAGE) were down 4.3% on Oct. 8 after the company announced disappointing top-line data from the phase II LIGHTWAVE study, which evaluated its neuropsychiatric candidate, dalzanemdor (SAGE-718) for treating mild cognitive impairment (MCI) and mild dementia in Alzheimer's Disease (AD). The stock continued to lose another 2.8% in the after-market hours. The double-blind, placebo-controlled LIGHTWAVE study evaluated the effects of dalzanemdor in participants with MCI or mild d ...

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sage Therapeutics investors who were adversely affected by alleged securities fraud between April 12, 2021 and July 23, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sag ...

文章核心观点 - 公司Sage Therapeutics正面临证券集体诉讼 [1][3] - 公司在治疗抑郁症、帕金森病认知障碍和必发性震颤等方面的药物研发存在问题 [3] - 公司对这些药物的临床试验结果和监管前景存在夸大宣传 [3] 公司概况 - Sage Therapeutics是一家专注于中枢神经系统疾病治疗的生物制药公司 [1] - 公司总部位于美国纽约 [2] - 公司自1995年成立以来已收回数亿美元投资者损失 [2] 诉讼相关 - 公司面临证券集体诉讼,投资者损失超过7.5万美元 [1] - 原告要求法院指定最大财务利益的投资者作为集体诉讼的首席原告 [4] - 公司鼓励任何掌握相关信息的人(包括内部人士、前员工、股东等)与律所联系 [4]

Sage Therapeutics (SAGE, Financial) experienced significant stock price fluctuations recently. Initially, the stock fell over 13% but later recovered, trading at a 0.5% gain to $6.756. The volatility followed the company's announcement that it would cease the development of its Alzheimer's drug. This decision came after the drug failed to meet primary goals in a mid-stage trial. ...

Sage Therapeutics (SAGE, Financial) reported a significant drop in its stock price, falling more than 30% in pre-market trading. It later stabilized at an 11% decline. This drop followed the announcement that their Alzheimer's treatment drug, dalzanemdor (SAGE-718), failed to meet primary endpoints in a mid-stage trial. The phase two LIGHTWAVE trial involved 174 participants diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's disease. The trial aimed to measure the disease's impact ...